Aug 22, 2019   SOURCE: PR NewsWire

Global Subcutaneous Drug Delivery Market to Surpass US$ 15.8 Billion by 2026

SEATTLE, Aug. 22, 2019 /PRNewswire/ - According to Coherent Market Insights, the global subcutaneous drug delivery market is valued at US$ 7,077.5 million in 2017, and is projected to exhibit a CAGR of 9.5% over the forecast period (2018-2026).

https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg

Key Trends and Analysis of the Global Subcutaneous Drug Delivery Market:

Increasing collaborations and partnerships by market players to develop innovative devices is expected to augment the market growth. In May 2018, Haselmeier and Common Sensing entered into partnership to develop a smart disposable injector pen platform using Haselmeier's subcutaneous drug delivery injection systems and Common Sensing's Gocap injector monitoring technology.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2933

Furthermore, rising prevalence of autoimmune diseases such as multiple sclerosis and new approvals for injector devices is expected to be major drivers for growth of the autoimmune segment in the global subcutaneous drug delivery market in the near future. For instance, in September 2015, Bayer HealthCare received the U.S. FDA approval for its BETACONNECT, an electronic auto-injector to be used with BETASERON (interferon beta-1b) indicated for treatment of relapsing-remitting multiple sclerosis (RRMS).

Buy this Report Now (For Single User License) @ https://www.coherentmarketinsights.com/insight/buy-now/2933

Key Market Takeaways:

    --  The global subcutaneous drug delivery market is expected to exhibit a
        CAGR of 9.5% during the forecast period (2018-2026), attributed to
        rising inclination of patient population towards self-administered
        drugs, increasing chronic diseases, adoption of novel drug delivery
        technologies to reduce needlestick injuries
    --  North America market is expected to show significant growth in adoption
        of prefilled syringes, owing to its advantages in treatment of diseases,
        precision, affordability, and easy techniques of self-medication.
        According to Centers for Disease Control and Prevention (CDC), 2014,
        around 29.1 million people in the U.S. were suffering from diabetes,
        accounting for 9.3% of the total population.
    --  Manufacturers in North America are focused on providing innovative
        treatment options to improve medication adherence, as the number of
        prescribed injectable therapies are increasing significantly. In 2016,
        Quio, a New York-based startup, was working to develop sensor-enabled
        drug injectors and companion software for chronic diseases. The company
        also received funding of US$ 1.05 Mn for the project.

· New approvals for prefilled syringes is expected to drive the segment growth in the global subcutaneous drug delivery market over the forecast period. For instance, in June 2017, Adamis Pharmaceuticals Corporation received the U.S. FDA approval for its EPINEPHRINE INJECTION, USP, 1:1000, for treatment of type I allergy reaction, which includes anaphylaxis. The epinephrine injection is sold under the trade name 'Symjepi'.

· Key players operating in the global subcutaneous drug delivery market include Becton Dickinson and Company, Novo Nordisk A/S, Johnson & Johnson, Sanofi S.A., Novartis International AG, Amgen, Inc., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Consort Medical plc, Eli Lilly and Company, and Merck & Co., Inc.

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/subcutaneous-drug-delivery-market-2933

Report Segmentation:

    --  Global Subcutaneous Drug Delivery Market, By Usability:
        --  Disposable
        --  Reusable
    --  Global Subcutaneous Drug Delivery Market, By Disease Indication:
        --  Auto-immune Disorders
        --  Neurological Disorders
        --  Oncology Disorders
        --  Hormonal Disorders
        --  Allergy & Infectious Disorders
        --  Ophthalmic Disorders
        --  Others
    --  Global Subcutaneous Drug Delivery Market, By Delivery Type:
        --  Prefilled Syringe
        --  Injector
        --  Prefilled Pen
        --  Vial (Syringe)
        --  Pump and Others
    --  Global Subcutaneous Drug Delivery Market, By Distribution Channel:
        --  Hospital Pharmacies
        --  Retail Pharmacies
        --  Online Pharmacies
    --  Global Subcutaneous Drug Delivery Market, By Region:
        --  North America
            --  By Country:
                --  U.S.
                --  Canada
        --  Latin America
            --  By Country:
                --  Brazil
                --  Mexico
                --  Argentina
                --  Rest of Latin America
        --  Europe
            --  By Country:
                --  Germany
                --  U.K.
                --  France
                --  Italy
                --  Spain
                --  Russia
                --  Rest of Europe
        --  Asia Pacific
            --  By Country:
                --  China
                --  India
                --  Japan
                --  Australia
                --  South Korea
                --  ASEAN
                --  Rest of Asia Pacific
        --  Middle East
            --  By Country/Region:
                --  GCC
                --  Israel
                --  Rest of Middle East
        --  Africa
            --  By Country/Region:
                --  South Africa
                --  Central Africa
                --  North Africa
    --  Company Profiles

Contact Us:
Mr. Raj Shah
Coherent Market Insights
1001 4th Ave.
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

View original content:http://www.prnewswire.com/news-releases/global-subcutaneous-drug-delivery-market-to-surpass-us-15-8-billion-by-2026--300905715.html

SOURCE Coherent Market Insights